Namenda (memantine) is an NMDA receptor agonist, or glutamate blocker, that has been FDA-approved for treating moderate to severe Alzheimer's. There is some anecdotal evidence it may be helpful in treating frontotemporal dementia (FTD).

Clinical experience of memantine in Alzheimer's disease
The true usefulness of any treatment is determined by how the agent performs in everyday clinical practice, how a patient feels and functions subjectively during treatment with the agent and how willi
http://www.touchneurology.com/files/article_pdfs/b...
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia
Background: The effectiveness of the 5 U.S. Food and Drug Administration-approved pharmacologic therapies for dementias in achieving clinically relevant improvements is unclear. Purpose: To review
http://www.annals.org/cgi/content/full/148/5/379
Efficacy of memantine for agitation in Alzheimer's dementia: a randomized double-blind placebo controlled trial -- commentary and summary
Namenda is known in Europe as Ebixa and generically as memantine. It is typically prescribed for mid-stage Alzheimer's disease. According to a new study conducted by researchers from the U.K., U.S.
Efficacy of memantine for agitation in Alzheimer's dementia: a randomized d...
Efficacy of memantine for agitation in Alzheimer's dementia: a randomized double-blind placebo controlled trial -- full paper
Background Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics wh
Efficacy of memantine for agitation in Alzheimer's dementia: a randomized d...
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis
INTRODUCTION: Behavioural disturbances are a common and distressing aspect of Alzheimer's disease (AD). This pooled analysis evaluated the specific benefits of memantine on behavioural disturbances in
Improvement in behavioural symptoms in patients with moderate to severe Alzheime...
Memantine for dementia
Background: Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia. Objectives: To determine efficacy and safety of memantine for people
http://mrw.interscience.wiley.com/cochrane/clsysre...
Meta-analysis of six-month memantine trials in Alzheimer's disease
BACKGROUND: Clinical trials have suggested benefits of memantine for all stages of Alzheimer's disease (AD). A meta-analysis of memantine trials in outpatients with probable AD was conducted. ME
http://www.ncbi.nlm.nih.gov/pubmed/19595910
Stopping Namenda
Dr. Kevin O'Neil's comment: Memantine is indicated for the treatment of moderate to severe Alzheimer's disease. Several clinical studies have demonstrated in such persons a favorable effect on cogniti
http://www.jamda.com/article/S1525-8610%2809%29005...